A glioblastoma study using CAR-T cell therapy targeting IL-13 receptor α2 (IL13Rα2) found that with IL13Rα2+ stimulation the CD8+ CAR-T cells demonstrated robust but short-term effector function and became exhausted more quickly, while CD4+ CAR-T cells outperformed CD8+ CAR-T cells with a superior antitumor response. This evidence concerns the gene IL13RA2 and glioblastoma.